
zzso zzso is a zzso B analogue that acts as a zzso zzso dynamics zzso zzso was approved in the United States in 2010 for the treatment of zzso breast cancer for patients who have received at least 2 zzso breast cancer zzso regimens, including an zzso and a zzso zzso is administered as a single agent at zzso zzso IV for 2 to 5 minutes on days 1 and 8 of a zzso zzso 

The goals of this article are to review zzso medication profile, including zzso zzso properties, zzso and zzso zzso are provided at the end of the article based on the published zzso 

zzso the Cochrane Central Register of Controlled zzso and Clinical zzso were searched from the beginning of each database through January 3, 2012, for relevant articles on human studies published in zzso Search terms included zzso zzso zzso and zzso Clinical trials, case reports, comparative studies, zzso evaluation studies, controlled clinical trials, and zzso controlled trials were included as search zzso The references from selected articles were also reviewed to identify additional zzso zzso the manufacturer of zzso zzso was also contacted for information regarding trials listed in zzso but not yet zzso 

One Phase III trial was identified that evaluated zzso for use in patients with zzso breast zzso Four Phase II trials were identified that studied zzso in patients with head and neck, zzso and zzso cell lung zzso The median overall survival among previously treated zzso breast cancer patients treated with zzso was zzso months compared with zzso months zzso zzso zzso with other active chemotherapy for this zzso In zzso cell lung cancer, median overall survival in zzso patients has been reported as zzso months in an zzso population and varies according to zzso zzso zzso months in zzso disease versus zzso months in zzso zzso Patients with head and neck or pancreatic zzso did not experience improvements in response rates or survival outcomes when treated with zzso in clinical zzso 

zzso is approved by the Food and Drug Administration for patients with previously treated zzso breast cancer and has demonstrated a survival benefit compared with standard treatment options in this zzso zzso cell lung cancer patients had improved response rates when treated with zzso in zzso zzso Phase II trials reported in abstract zzso zzso was not effective in the treatment of head and neck or pancreatic cancer in Phase II zzso 

